Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tretazicar (NSC-115829) 是一种抗肿瘤前药,由 NAD(P)H 醌氧化还原酶 2 激活。它在酶促活化后生成细胞毒性双功能烷基剂,可以形成 DNA-DNA 链间交联。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 179 | 现货 | ||
5 mg | ¥ 395 | 现货 | ||
10 mg | ¥ 597 | 现货 | ||
25 mg | ¥ 1,190 | 现货 | ||
50 mg | ¥ 1,790 | 现货 | ||
100 mg | ¥ 2,670 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 437 | 现货 |
产品描述 | CB1954(Tretazicar (NSC-115829)), an anticancer prodrug, is activated by NAD(P)H quinone oxidoreductase 2. It is converted in the presence of the enzyme NQO2 and co-substrate caricotamide ( EP-0152R) (EP) into a potent cytotoxic bifunctional alkylating agent. |
体外活性 | In the NPC cell line CNE1, toxic CB1954 enhances cells killing. The overexpression of nitroreductase oxidored nitro domain-containing protein 1 (NOR1) reduce the 4 nitro group of CB1954, a potent cytotoxin, in order to convert the monofunctional alkylating agent CB1954 into a toxic form. In the HepG2 cell line, the NOR1 gene upregulates of Grb2 expression and activates of MAPK signal transduction leading to enhances CB1954 mediated cell cytotoxicity. |
体内活性 | The NTR/CB1954 system, which is in a dose-dependent effect, are used for specific ablation of cells in vivo. NTR-mediated cell killing by CB1954, which is activated cross-links, presumed through triggers the apoptosis cascade resulting in rapid cell death. Selective and potent cells killing by NTR-CB1954 does not require a functional p53. |
细胞实验 | HepG2 cells,which are maintained in RPMI 1640 supplemented with 10% fetal calf serum (FCS) in a humidified culture incubator at 37?C with 5% CO2 and 95% air, grow to ~80% confluence are washed with PBS and treated with r CB1954(4-10 μmol/L) for 48hours. |
动物实验 | RED 40 female mice,which express high levels of BLG-NTR transgene in the mammary gland and nontransgenic control mice on lactation day 6, were injected intraperitoneally (i.p.)with 50 mg/kg CB1954 dissolved in arachis oil containing 10% acetone. |
别名 | 5-Aziridino-2,4-dinitrobenzamide, CB1954, NSC 115829 |
分子量 | 252.18 |
分子式 | C9H8N4O5 |
CAS No. | 21919-05-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 47 mg/mL (186.4 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.9654 mL | 19.8271 mL | 39.6542 mL | 99.1355 mL |
5 mM | 0.7931 mL | 3.9654 mL | 7.9308 mL | 19.8271 mL | |
10 mM | 0.3965 mL | 1.9827 mL | 3.9654 mL | 9.9136 mL | |
20 mM | 0.1983 mL | 0.9914 mL | 1.9827 mL | 4.9568 mL | |
50 mM | 0.0793 mL | 0.3965 mL | 0.7931 mL | 1.9827 mL | |
100 mM | 0.0397 mL | 0.1983 mL | 0.3965 mL | 0.9914 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tretazicar 21919-05-1 DNA Damage/DNA Repair DNA Alkylator/Crosslinker DNA Alkylation NQO1 5-Aziridino-2,4-dinitrobenzamide CB 1954 rat bifunctional Inhibitor inhibit agent cross-link 256 line 4-hydroxylamine Walker NSC115829 NSC-115829 DNA CB-1954 CB1954 NSC 115829 tumour inhibitor